Aspirin and eicosapentaenoic acid may arrest progressive IgA nephropathy: A potential alternative to immunosuppression

Junichi Hirahashi, Norio Hanafusa, Takehiko Wada, Makoto Arita, Keiichi Hishikawa, Matsuhiko Hayashi, Masaomi Nangaku

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Immunoglobulin (Ig) A nephropathy is a prevalent form of primary glomerulonephritis, which leads to end-stage renal failure in a significant proportion of patients. Immunotherapy, including steroid use, is widely used to induce disease remission; however, it can cause serious side effects. We herein report 3 cases of progressive IgA nephropathy and their successful treatment with a combination of aspirin and eicosapentaenoic acid (EPA) without the use of steroids. The precise mechanism responsible for the combination therapy is still unknown; however, aspirin may potentiate the production of anti-inflammatory lipid mediators derived from EPA. Further clinical trials are required to substantiate this treatment regimen.

Original languageEnglish
Pages (from-to)2377-2382
Number of pages6
JournalInternal Medicine
Volume54
Issue number18
DOIs
Publication statusPublished - 2015 Sep 15

Keywords

  • Aspirin
  • Eicosapentaenoic acid
  • IgA nephropathy
  • Steroids

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Aspirin and eicosapentaenoic acid may arrest progressive IgA nephropathy: A potential alternative to immunosuppression'. Together they form a unique fingerprint.

  • Cite this